ProCE Banner Activity

Multidisciplinary Expert Insights and Guidance on Using PARP Inhibitors in Ovarian Cancer

Slideset Download
Download these slides to review expert insights on optimizing the use of PARP inhibitors in ovarian cancer.

Released: September 25, 2019

Expiration: September 23, 2020

Share

Faculty

Laura Alwan

Laura Alwan, PharmD, BCOP

Clinical Instructor
University of Washington School of Pharmacy
Oncology Clinical Pharmacist
Seattle, Washington

Virginia Bayer

Virginia Bayer, BSN, RN, OCN

Research Nurse Supervisor
Department of Gynecology Oncology
MD Anderson Cancer Center
Houston, Texas

Robert E. Coleman

Robert E. Coleman, MD, FRCP

Professor and Honorary Consultant Medical Oncologist
Cancer Clinical Trials Centre
Academic Unit of Clinical Oncology
Weston Park Hospital
Sheffield, England

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by independent educational grants from

Clovis Oncology

Tesaro

Faculty Disclosure

Primary Author

Laura Alwan, PharmD, BCOP

Clinical Instructor
University of Washington School of Pharmacy
Oncology Clinical Pharmacist
Seattle, Washington

Virginia Bayer, BSN, RN, OCN

Research Nurse Supervisor
Department of Gynecology Oncology
MD Anderson Cancer Center
Houston, Texas

Robert E. Coleman, MD, FRCP

Professor and Honorary Consultant Medical Oncologist
Cancer Clinical Trials Centre
Academic Unit of Clinical Oncology
Weston Park Hospital
Sheffield, England